Quantitative SARS-CoV-2 spike-specific immunoglobulin G (IgG) antibody titers were measured with the Access SARS-CoV-2 IgG assay (Beckman Coulter C74339; Beckman Coulter Inc., Brea, CA, USA), according to the manufacturer’s instructions. The chemiluminescent immunoassay is based on the use of paramagnetic particles coated with recombinant SARS-CoV-2 receptor-binding domain protein. Particles are incubated with the plasma sample containing the specific antibodies; materials bound to the solid phase are held in a magnetic field while unbound materials are washed away. A monoclonal anti-human IgG alkaline phosphatase conjugate is added to bind the IgG antibodies captured on the particles. After washing a second separation to remove unbound conjugate is performed. A chemiluminescent substrate is added and light generated by the reaction is measured with a luminometer. The light production is compared to the standard curve build with the cut-off value defined during calibration of the instrument. Access SARS-CoV-2 IgG positive and negative Calibrators are provided by the manufacturer. Plasma concentration of specific IgG was expressed as international units/mL (IU/mL). Blood samples were collected prior to vaccination (Pre-vac), 14 days (T1), and 90 days (T2) following the booster vaccination. Plasma was isolated and stored at -20℃ until used.
Access sars cov 2 igg assay
Manufactured by Beckman Coulter
Sourced in United States
The Access SARS-CoV-2 IgG assay is an in vitro diagnostic test used to detect the presence of IgG antibodies to the SARS-CoV-2 virus in human serum and plasma samples. The assay is designed to aid in the diagnosis of COVID-19 infection.
Automatically generated - may contain errors
3 protocols using access sars cov 2 igg assay
1
Quantitative SARS-CoV-2 Spike IgG Assay
2
SARS-CoV-2 Antibody and Neutralization Assays
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Samples from vaccinated participants were tested for antibodies against SARS-CoV-2 receptor-binding domain with the Access SARS-CoV-2 IgG assay (Beckman Coulter).11 (link),12 (link) Anti-N antibodies were tested with the Platelia SARS-CoV-2 Total Ab Assay (Bio-Rad) according to manufacturer instructions. The SARS-CoV-2 pseudovirus neutralization assay was performed as described previously7 (link) with the use of a green fluorescent protein reporter–based pseudotyped virus with a vesicular stomatitis virus backbone coated with SARS-CoV-2 S protein. The lower level of diagnostic detection for IgG is 0.62, and the lower level that is considered neutralizing is 16. Additional information about antibody testing is provided in Supplementary Methods Section S3.
3
Multi-Assay Validation of SARS-CoV-2 Antibodies
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
SARS-CoV-2 antibodies were screened using the Elecsys Anti-SARS-CoV-2 assay on the Cobas e801 analyzer (Roche Diagnostics, Mannheim, Germany). This kit detects antibodies against the nucleocapsid protein of SARS-CoV-2 with a specificity and sensitivity of 100% and 99.8%, respectively [12 ]. Positive samples were further validated using 5 additional assays that detected various antigens using different detection principles to improve the specificity of the test results: the Architect SARS-CoV-2 IgG assay (Abbott Laboratories, Chicago, IL, USA), Access SARS-CoV-2 IgG assay (Beckman Coulter, Pasadena, CA, USA), R-FIND COVID-19 ELISA (SG Medical, Inc., Seoul, Korea), SGTi-flex COVID19 IgM/IgG (Sugentech, Daejeon, Korea) rapid kits and the plaque reduction neutralizing test (PRNT) for neutralizing antibodies. All test kit assays were performed according to the manufacturer’s instructions.
A sample was ultimately considered positive for SARS-CoV-2 antibodies if both the screening test and at least 1 of the 5 additional tests were positive (Figure 1 ). All seropositive subjects were checked for their infection and travel history during the pandemic, along with their previous polymerase chain reaction test results.
A sample was ultimately considered positive for SARS-CoV-2 antibodies if both the screening test and at least 1 of the 5 additional tests were positive (
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!